Misoprostol Matches Oxytocin for Treating Postpartum Hemorrhage in Clinical Trial

Globally, postpartum hemorrhage (PPH), often caused by uterine atony (when the uterus fails to contract adequately after childbirth), remains a leading cause of maternal mortality. While oxytocin is the gold standard treatment, its requirement for intravenous administration and cold chain storage limits its accessibility, especially in low-resource settings. This study directly compared the effectiveness of sublingual misoprostol, an orally administered and heat-stable drug, against intravenous oxytocin for treating primary PPH, considering scenarios both with and without prior prophylactic uterotonic use.

The trial demonstrated that misoprostol was non-inferior to oxytocin in treating PPH, achieving comparable rates of treatment success. In women who had received prophylactic uterotonics, the mean blood loss after treatment was 300 mL in the misoprostol group compared to 280 mL in the oxytocin group, with no statistically significant difference (p=0.25). Similarly, for women who had not received prophylactic uterotonics, mean blood loss was 350 mL for misoprostol versus 320 mL for oxytocin, also showing no significant difference (p=0.18). The primary outcome, treatment success (defined as cessation of bleeding and no need for additional uterotonics), was achieved in 85% of the misoprostol group and 88% of the oxytocin group, confirming comparable efficacy between the two interventions. Adverse events, predominantly mild shivering and fever, were more frequently observed with misoprostol but were generally self-limiting.